ChiCTR2600124786 版本V1.0 版本创建时间2026/05/18 10:42:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600124786 

最近更新日期:

Date of Last Refreshed on:

2026-05-18 10:42:16 

注册时间:

Date of Registration:

2026-05-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

比较奥赛利定和小剂量艾司氯胺酮对甲状腺切除患者苏醒期拔管呛咳反应的影响

Public title:

Comparing the effects of oxyline and low-dose esketamine on the coughing reactions during extubation in patients after thyroidectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

比较奥赛利定和小剂量艾司氯胺酮对甲状腺切除患者苏醒期拔管呛咳反应的影响

Scientific title:

Comparing the effects of oxyline and low-dose esketamine on the coughing reactions during extubation in patients after thyroidectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴雄志 

研究负责人:

吴雄志 

Applicant:

Wu Xiongzhi  

Study leader:

Wu Xiongzhi  

申请注册联系人电话:

Applicant telephone:

+86 155 5121 2726

研究负责人电话:

Study leader's
telephone:

+86 155 5121 2726

申请注册联系人传真 :

Applicant Fax:

+86 155 5121 2726

研究负责人传真:

Study leader's fax:

+86 155 5121 2726

申请注册联系人电子邮件:

Applicant E-mail:

wuxz202306@163.com

研究负责人电子邮件:

Study leader's E-mail:

wuxz202306@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

安庆市立医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国安徽省安庆市天柱山东路87号

研究负责人通讯地址:

中国安徽省安庆市天柱山东路87号

Applicant address:

No. 87 East Tianzhu Road, Anqing City, Anhui Province, China

Study leader's address:

No. 87 East Tianzhu Road, Anqing City, Anhui Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安庆市立医院

Applicant's institution:

Anqing Municipal Hospital

研究负责人所在单位:

安庆市立医院

Affiliation of the Leader:

Anqing Municipal Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医学伦审(2026)第50号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

安庆市立医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Anqing Municipal Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-08 00:00:00

伦理委员会联系人:

邵美满

Contact Name of the ethic committee:

Shao Meiman

伦理委员会联系地址:

中国安徽省安庆市天柱山东路87号

Contact Address of the ethic committee:

No. 87 East Tianzhu Road, Anqing City, Anhui Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 556 522 3930

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

安庆市立医院

Primary sponsor:

Anqing Municipal Hospital

研究实施负责(组长)单位地址:

中国安徽省安庆市天柱山东路87号

Primary sponsor's address:

No. 87 East Tianzhu Road, Anqing City, Anhui Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

安庆

Country:

China

Province:

Anhui

City:

Anqing

单位(医院):

安庆市立医院

具体地址:

中国安徽省安庆市天柱山东路87号

Institution
hospital:

Anqing Municipal Hospital

Address:

No. 87 East Tianzhu Road, Anqing City, Anhui Province, China

经费或物资来源:

自筹经费

Source(s) of funding:

Self-raised

研究疾病:

甲状腺手术  

Target disease:

thyroid surgery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察奥赛利定与小剂量艾司氯胺酮对甲状腺切除患者苏醒期拔管呛咳反应的影响  

Objectives of Study:

Observation of the effects of oxyline and low-dose esketamine on the coughing reaction during extubation in patients after thyroidectomy during the recovery period

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄 18-65岁; 2.BMI 18-30 kg/m2; 3.ASA I-III级; 4.计划在全身麻醉下接受择期甲状腺切除手术的患者; 5.沟通交流正常; 6.自愿受试并签署知情同意书。

Inclusion criteria

1. Age: 18 - 65 years old; 2. BMI: 18 - 30 kg/m2; 3. ASA grade I - III; 4. Patients planning to undergo elective thyroidectomy under general anesthesia; 5. Normal communication and interaction; 6. Voluntary participants and having signed the informed consent form.

排除标准:

1.严重高血压; 2.诊断为睡眠呼吸暂停的患者; 3.阿片类药物或艾司氯胺酮过敏史及存在阿片类药物或艾司氯胺酮禁忌症患者; 4.长期使用阿片类药物治疗; 5.心电图异常(筛查时QTc F间期>470 ms); 6.精神疾病患者 ; 7.肝肾功能不全患者; 8.孕妇或哺乳期妇女; 9.有颅内压升高严重风险的患者。

Exclusion criteria:

1. Severe hypertension; 2. Patients diagnosed with sleep apnea; 3. Patients with a history of allergy to opioids or esketamine and those with contraindications to opioids or esketamine; 4. Long-term use of opioid treatment; 5. Abnormal electrocardiogram (during screening, QTc F interval > 470 ms); 6. Patients with mental disorders; 7. Patients with impaired liver and kidney function; 8. Pregnant or lactating women; 9. Patients with a high risk of intracranial pressure increase.

研究实施时间:

Study execute time:

From 2026-05-22 00:00:00 To 2027-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-22 00:00:00 To 2027-07-01 00:00:00

干预措施:

Interventions:

组别:

奥赛利定组(O组)

样本量:

110

Group:

Oxyramine group (Group O)

Sample size:

干预措施:

患者手术结束前30 min给予奥赛利定2 mg

干预措施代码:

Intervention:

2 mg of oxyramine was administered to the patient 30 minutes before the surgery was completed.

Intervention code:

组别:

艾司氯胺酮组(E组)

样本量:

110

Group:

Esketamine group (Group E)

Sample size:

干预措施:

患者手术结束前30 min给与艾司氯胺酮0.25 mg/kg

干预措施代码:

Intervention:

0.25 mg/kg of esketamine was administered to the patient 30 minutes before the surgery was completed.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

安庆 

Country:

China

Province:

Anhui

City:

Anqing

单位(医院):

安庆市立医院 

单位级别:

三甲 

Institution
hospital:

Anqing Municipal Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

拔管时呛咳反应发生的严重程度

指标类型:

次要指标

Outcome:

The severity of the choking and coughing reactions during tube removal

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后疼痛NRS评分

指标类型:

次要指标

Outcome:

Postoperative pain NRS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后咽痛咽干

指标类型:

次要指标

Outcome:

Postoperative sore throat and dry throat

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后声音嘶哑

指标类型:

次要指标

Outcome:

Post-operative hoarseness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉药物停止输注时、意识恢复配合睁眼时、拔管时、拔管后1 min、拔管后5 min血流动力学标

指标类型:

次要指标

Outcome:

When the anesthetic drugs are stopped being administered, when consciousness returns and the eyes are opened cooperatively, during extubation, 1 minute after extubation, 5 minutes after extubation, he

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

苏醒时间;拔管时间

指标类型:

次要指标

Outcome:

Awakening time; Tube removal time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PACU停留期间不良反应

指标类型:

次要指标

Outcome:

Adverse reactions during the stay in the PACU

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

拔管时呛咳反应发生率

指标类型:

主要指标

Outcome:

The incidence of coughing reflex during extubation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用区组随机化方法将220例甲状腺切除患者根据入院时间,随机分为艾司艾司氯胺酮组(E组)和奥赛利定组(O组)。首先通过计算机生成区组长度为4的随机序列,确保每个区组内E组和O组病例数均衡分配

Randomization Procedure (please state who generates the random number sequence and by what method):

: In this study, 220 patients who underwent thyroidectomy were randomly assigned to the esketamine group (E group) and the oliceridine group (O group) based on their admission time using block randomization. Firstly, a random sequence with a block length of 4 was generated by computer to ensure an even distribution of cases between the E group and the O group within each block.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

日期:试验完成后的六个月。具体网站:临床试验公共管理平台ResMan (www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date: Six months after trial completion. Website: Clinical Trial Public Management Platform ResMan (www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-18 10:42:16